Cargando…

Benefit of Apabetalone on Plasma Proteins in Renal Disease

INTRODUCTION: Apabetalone, a small molecule inhibitor, targets epigenetic readers termed BET proteins that contribute to gene dysregulation in human disorders. Apabetalone has in vitro and in vivo anti-inflammatory and antiatherosclerotic properties. In phase 2 clinical trials, this drug reduced the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wasiak, Sylwia, Tsujikawa, Laura M., Halliday, Christopher, Stotz, Stephanie C., Gilham, Dean, Jahagirdar, Ravi, Kalantar-Zadeh, Kamyar, Robson, Richard, Sweeney, Michael, Johansson, Jan O., Wong, Norman C., Kulikowski, Ewelina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Translational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976837/ https://www.ncbi.nlm.nih.gov/pubmed/29854980 http://dx.doi.org/10.1016/j.ekir.2017.12.001

Ejemplares similares

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
por: Wasiak, Sylwia, et al.
Publicado: (2017)

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease
por: Wasiak, Sylwia, et al.
Publicado: (2020)

Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment
por: Gilham, Dean, et al.
Publicado: (2023)

APABETALONE (RVX-208) REDUCES ACE2 PROTEIN ABUNDANCE AND PREVENTS SARS-COV-2 SPIKE PROTEIN BINDING TO HUMAN LUNG CELLS, A MOA THAT COULD ATTENUATE VIRAL ENTRY
por: Fu, Li, et al.
Publicado: (2021)

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
por: Tsujikawa, Laura M., et al.
Publicado: (2019)

Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
por: Fu, Li, et al.
Publicado: (2023)

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
por: Sarsons, Christopher D., et al.
Publicado: (2023)

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
por: Wasiak, Sylwia, et al.
Publicado: (2016)

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
por: Fu, Li, et al.
Publicado: (2022)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
por: Gilham, Dean, et al.
Publicado: (2021)

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
por: Nicholls, Stephen J., et al.
Publicado: (2021)

BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
por: Wasiak, Sylwia, et al.
Publicado: (2020)

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
por: Gilham, D, et al.
Publicado: (2021)

Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease
por: Haarhaus, Mathias, et al.
Publicado: (2020)

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
por: Toth, Peter P., et al.
Publicado: (2022)

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: A1C remains the gold standard outcome predictor in diabetic dialysis patients
por: Kalantar-Zadeh, Kamyar
Publicado: (2012)

Patient education for phosphorus management in chronic kidney disease
por: Kalantar-Zadeh, Kamyar
Publicado: (2013)

Incremental and Once- to Twice-Weekly Hemodialysis: From Experience to Evidence
por: Obi, Yoshitsugu, et al.
Publicado: (2017)

Combining Peritoneal and Hemodialysis in the Same Patient: Furthering Precision Medicine in Dialysis Transitions
por: Sy, John, et al.
Publicado: (2020)

Treating hyponatremia fast but modestly: counterbalancing risks and the fear of osmotic demyelination syndrome
por: Murt, Ahmet, et al.
Publicado: (2023)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020)

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
por: Jonker, D J, et al.
Publicado: (2014)

Benefits of Incremental Hemodialysis Seen in a Historical Cohort Study
por: Chen, Weisheng, et al.
Publicado: (2021)

Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients?
por: Rhee, Connie M., et al.
Publicado: (2014)

Perspective: Overweight, mortality and survival
por: Flegal, Katherine M., et al.
Publicado: (2013)

Nutrition Intervention for Advanced Stages of Diabetic Kidney Disease
por: Goldstein-Fuchs, Jordi, et al.
Publicado: (2015)

Implications of the Long Inter-Dialytic Gap: A Problem of Excess Accumulation vs. Excess Removal?
por: Rhee, Connie M., et al.
Publicado: (2015)

Estimating Residual Kidney Function With and Without Urine Clearance Measures: A Useful Tool for Incremental Dosing of Dialysis
por: Hanna, Ramy M., et al.
Publicado: (2019)

Precision Nutrition and Personalized Diet Plan for Kidney Health and Kidney Disease Management
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2020)

Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2020)

How important is dietary management in chronic kidney disease progression? A role for low protein diets
por: Ko, Gang-Jee, et al.
Publicado: (2021)

Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
por: Griffiths, R W, et al.
Publicado: (2005)

Kidney cachexia or protein‐energy wasting in chronic kidney disease: facts and numbers
por: Koppe, Laetitia, et al.
Publicado: (2019)

Ramatroban as a Novel Immunotherapy for COVID-19
por: Gupta, Ajay, et al.
Publicado: (2020)

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
por: Weickhardt, A J, et al.
Publicado: (2015)

Exercise and Health: Can Biotechnology Confer Similar Benefits?
por: Williams, R. Sanders, et al.
Publicado: (2005)

Averting the legacy of kidney disease – focus on childhood
por: Ingelfinger, Julie R., et al.
Publicado: (2016)

In time: averting the legacy of kidney disease – focus on childhood
por: Ingelfinger, Julie R., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_llg6f7c02vnpe3icsob070ik21